All Drug Discovery articles – Page 21
-
NewsCOVID-19 and flu could awaken hidden breast cancer cells
Scientists have discovered that infections like COVID-19 and flu can “wake up” dormant breast cancer cells – triggering new tumour growth in the lungs.
-
NewsNew stroke drug reduces brain damage by 60 percent in preclinical study
Cambridge researchers have discovered a new drug that could dramatically improve stroke recovery by reducing brain damage caused when blood flow is restored.
-
NewsCDK4/6 and PARP combo improves prostate cancer treatment
Researchers at VHIO have discovered a new way to overcome drug resistance in metastatic prostate cancer – by combining CDK4/6 inhibitors with follow-up therapies.
-
NewsNew drug combo targets PRMT5 to fight deadly cancers
Scientists at Virginia Tech’s Fralin Biomedical Research Institute have identified a promising drug target – PRMT5 – that could make treatment-resistant lung, brain and pancreatic cancers more vulnerable to therapy.
-
ArticleAntibodies come full circle: biopharma back at the bench
Recombinant antibody technology is redefining research standards - bringing biopharma-grade precision, consistency, and customisation to the lab. Discover how advances like Fc engineering and chimerisation are accelerating progress from basic discovery to clinical insight.
-
NewsHow FtsZ and ZapA proteins drive bacterial cell division
Japanese researchers have discovered how the bacterial proteins FtsZ and ZapA work together to drive cell division – a discovery that could guide the development of new antibacterial treatments.
-
ArticleFrom lab to clinic: the rise of Radio-DARPins in oncology
As radioligand therapy continues to show promise, its application in solid tumours remains limited by long-standing biological challenges. In this interview, Julien Torgue, CSO at Orano Med, discusses a new collaborative platform – Radio-DARPins – and how it could help overcome key barriers to clinical progress.
-
NewsELRIG announces keynote speakers for Drug Discovery 2025 in Liverpool
ELRIG (European Laboratory Research & Innovation Group) has announced the keynote speakers for Drug Discovery 2025, Europe’s premier life sciences conference, taking place at ACC Liverpool from 21–22 October 2025.
-
ArticleWhy smarter financial planning could be key to clinical trial success
Effective financial management is vital for clinical trial success, yet many preclinical and clinical companies face inefficiencies due to outdated systems. Jennifer Kyle, CEO of Condor Software, explains how advanced financial platforms can streamline processes, improve forecasting and ensure better resource allocation throughout drug development.
-
NewsDeep-sea sugar EPS3.9 sparks immune attack on tumours
Scientists have isolated a sugar molecule from deep-sea bacteria that triggers pyroptosis - a form of inflammatory cell death - to halt tumour growth - highlighting the potential of marine microbes in drug development.
-
WebinarInnovating Obesity Drug Discovery: Trends, Challenges, and Translational Strategies
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk.
-
ArticleFixing failed drugs: AI solutions for toxicity in drug discovery – part 3
What role could large language models and AI agents play in drug safety? In Part 3, Layla Hosseini-Gerami of Ignota Labs discusses how emerging technologies might make toxicity analysis faster, more accessible and part of the drug discovery workflow from day one.
-
NewsNew 3D bioprinted lung tissue could transform respiratory research
UBC Okanagan researchers have developed a new 3D bio-printed lung model that closely mimics the complexity of human tissue – providing scientists with a powerful new tool for studying respiratory diseases.
-
NewsAutoimmune breakthrough: Egr-1 regulates treg cells in diseases like MS
Scientists have found a key mechanism driving immune regulation in autoimmune diseases like MS and IBD – which could lead to new targeted treatments.
-
NewsDiscovery of hidden survival mechanism in MRSA points to new drug targets
In the fight against antibiotic-resistant bacteria, researchers at Michigan State University (MSU) have made a discovery that could change how we target deadly pathogens like Staphylococcus aureus and its drug-resistant strain - MRSA.
-
News€15M-backed tech targets tumour complexity
Paris-based One Biosciences, a precision oncology biotech company, has raised €15 million in Series A financing to accelerate the development of its AI-powered single-cell tumour profiling platform.
-
NewsNew standards for brain organoids aim to boost drug discovery
A new international framework introduces rigorous validity standards for the use of brain organoids and iPSC-derived models in studying neuropsychiatric disorders. These guidelines aim to accelerate drug discovery and bring precision treatments closer to reality.
-
NewsNew drug GAI-17 reduces stroke-induced brain cell death
A new stroke treatment, GAI-17, developed by researchers in Japan, has shown encouraging results in reducing brain cell death and paralysis in animal models – potentially allowing for future development of treatments for other brain disorders.
-
ArticleThe future of CNS drug development: signs of real progress
New therapeutic approaches are emerging for CNS disorders – but can they overcome the toughest barriers in drug development? Find out what is driving progress and what still stands in the way.
-
ArticleOutsmarting immune suppression through GPCR innovation
Immune resistance is one of cancer’s toughest tricks. By rethinking how we target GPCRs, scientists may finally have a way to modulate it with precision.